Sanofi-Aventis agreed to co-develop Kyowa Hakko Kirin's anti-LIGHT fully human monoclonal antibody as a treatment for inflammation. The licensing deal, worth as much as $315 million, grants Sanofi worldwide rights to the drug, although the companies will jointly work on the product in Japan and Asia.

Full Story:

Related Summaries